Fundraising FoxBioqube Ventures — 2021 Investments
2 investments dated 2021 · listed companies and verified rows first · show all
Egle Therapeuticsegle-tx.cominSeries A · Oct 2021 · $47M
Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer.
Biotech
Fiorella Kotsias(Chief Scientific Officer)inBernard Vanhove(Chief Development Officer)in
BoardMichel Detheux(Chairman)in
Co-investorsEQT Life SciencesFund+JDRF T1D Fund
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Anavo Therapeutics
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.